Evolus Inc (NASDAQ:EOLS) – Investment analysts at SunTrust Banks lowered their FY2022 EPS estimates for shares of Evolus in a research note issued on Monday, November 19th. SunTrust Banks analyst J. Boris now expects that the company will post earnings of $2.28 per share for the year, down from their prior forecast of $2.55. SunTrust Banks currently has a “Buy” rating and a $27.00 target price on the stock.

Several other research firms also recently commented on EOLS. Cantor Fitzgerald set a $35.00 price target on shares of Evolus and gave the company a “buy” rating in a research report on Wednesday, August 29th. Zacks Investment Research upgraded shares of Evolus from a “hold” rating to a “buy” rating and set a $22.00 price target for the company in a research report on Thursday, July 26th. Finally, JMP Securities reiterated an “outperform” rating and issued a $35.00 price target on shares of Evolus in a research report on Thursday, August 2nd. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $30.40.

EOLS stock opened at $13.84 on Tuesday. Evolus has a 12 month low of $6.75 and a 12 month high of $39.50. The firm has a market capitalization of $403.12 million and a P/E ratio of -51.26.

Evolus (NASDAQ:EOLS) last released its quarterly earnings results on Monday, November 5th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.09).

In other Evolus news, Director Kristine Romine purchased 10,000 shares of Evolus stock in a transaction that occurred on Wednesday, August 22nd. The stock was purchased at an average price of $19.83 per share, for a total transaction of $198,300.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Michael M. Jafar purchased 12,800 shares of Evolus stock in a transaction that occurred on Friday, September 14th. The stock was acquired at an average price of $20.83 per share, with a total value of $266,624.00. The disclosure for this purchase can be found here.

A number of institutional investors have recently made changes to their positions in the business. TIAA CREF Investment Management LLC raised its position in Evolus by 51.2% during the 3rd quarter. TIAA CREF Investment Management LLC now owns 12,259 shares of the company’s stock worth $228,000 after buying an additional 4,151 shares during the last quarter. Teachers Advisors LLC raised its position in Evolus by 58.8% during the 3rd quarter. Teachers Advisors LLC now owns 13,720 shares of the company’s stock worth $255,000 after buying an additional 5,081 shares during the last quarter. Luminus Management LLC purchased a new position in Evolus during the 3rd quarter worth $3,423,000. Point72 Asset Management L.P. purchased a new position in Evolus during the 3rd quarter worth $14,113,000. Finally, PointState Capital LP purchased a new position in Evolus during the 3rd quarter worth $12,289,000. Institutional investors own 15.18% of the company’s stock.

Evolus Company Profile

Evolus, Inc provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.

See Also: Liquidity

Earnings History and Estimates for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.